Published in Cancer Weekly, April 27th, 1998
But analysts and officials of the companies, Myriad Genetics Inc., Salt Lake City, Utah, and Oncormed Inc., Gaithersburg, Maryland, said that any increase in breast cancer gene screening is likely to be slow and steady rather than explosive because of a variety of factors.
They cited side effects from tamoxifen, steep costs of breast cancer gene tests and lingering societal distrust of genetic...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.